BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 28205331)

  • 1. New insights to the mechanisms underlying atherosclerosis in rheumatoid arthritis.
    Mahmoudi M; Aslani S; Fadaei R; Jamshidi AR
    Int J Rheum Dis; 2017 Mar; 20(3):287-297. PubMed ID: 28205331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular Risk in Rheumatoid Arthritis and Mechanistic Links: From Pathophysiology to Treatment.
    Fragoulis GE; Panayotidis I; Nikiphorou E
    Curr Vasc Pharmacol; 2020; 18(5):431-446. PubMed ID: 31258091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular risk in rheumatoid arthritis: how to lower the risk?
    van Breukelen-van der Stoep DF; Klop B; van Zeben D; Hazes JM; Castro Cabezas M
    Atherosclerosis; 2013 Nov; 231(1):163-72. PubMed ID: 24125429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Rheumatoid arthritis, inflammation, and atherosclerosis].
    Hürlimann D; Enseleit F; Ruschitzka F
    Herz; 2004 Dec; 29(8):760-8. PubMed ID: 15599672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Atherosclerosis and rheumatoid arthritis].
    Löwenhoff T; Głuszko P
    Przegl Lek; 2005; 62(12):1506-9. PubMed ID: 16786783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential effect of anti-inflammatory treatment on reducing the cardiovascular risk in rheumatoid arthritis.
    Chighizola C; Schioppo T; Ingegnoli F; Meroni PL
    Curr Vasc Pharmacol; 2012 Sep; 10(5):639-46. PubMed ID: 22272912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rheumatoid Arthritis Pharmacotherapies: Do They Have Anti-Atherosclerotic Activity?
    Giles JT
    Curr Rheumatol Rep; 2016 May; 18(5):27. PubMed ID: 27032790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular risk in rheumatoid arthritis.
    Nurmohamed MT
    Autoimmun Rev; 2009 Jul; 8(8):663-7. PubMed ID: 19393192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology.
    Dixon WG; Symmons DP
    Ann Rheum Dis; 2007 Sep; 66(9):1132-6. PubMed ID: 17251223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carotid atherosclerosis, disease measures, oxidized low-density lipoproteins, and atheroprotective natural antibodies for cardiovascular disease in early rheumatoid arthritis -- an inception cohort study.
    Ajeganova S; de Faire U; Jogestrand T; Frostegård J; Hafström I
    J Rheumatol; 2012 Jun; 39(6):1146-54. PubMed ID: 22589258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular disease in rheumatoid arthritis: Current perspectives on assessing and mitigating risk in clinical practice.
    Giles JT
    Best Pract Res Clin Rheumatol; 2015; 29(4-5):597-613. PubMed ID: 26697769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accelerated Atherosclerosis in Rheumatoid Arthritis: Mechanisms and Treatment.
    Reiss AB; Silverman A; Khalfan M; Vernice NA; Kasselman LJ; Carsons SE; De Leon J
    Curr Pharm Des; 2019; 25(9):969-986. PubMed ID: 31208307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Extent of Subclinical Atherosclerosis Is Partially Predicted by the Inflammatory Load: A Prospective Study over 5 Years in Patients with Rheumatoid Arthritis and Matched Controls.
    Södergren A; Karp K; Bengtsson C; Möller B; Rantapää-Dahlqvist S; Wållberg-Jonsson S
    J Rheumatol; 2015 Jun; 42(6):935-42. PubMed ID: 25877503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis and Low Cardiovascular Risk: The Role of von Willebrand Factor Activity.
    Ristić GG; Subota V; Lepić T; Stanisavljević D; Glišić B; Ristić AD; Petronijević M; Stefanović DZ
    PLoS One; 2015; 10(8):e0130462. PubMed ID: 26247590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TNF as a Target of Inflammation in Rheumatoid Arthritis.
    Yamanaka H
    Endocr Metab Immune Disord Drug Targets; 2015; 15(2):129-34. PubMed ID: 25772178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Will antirheumatic treatment improve cardiovascular outcomes in patients with rheumatoid arthritis?
    Pieringer H; Pichler M; Pohanka E; Hoppe UC
    Curr Pharm Des; 2014; 20(4):486-95. PubMed ID: 23565635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
    van Halm VP; Nurmohamed MT; Twisk JW; Dijkmans BA; Voskuyl AE
    Arthritis Res Ther; 2006; 8(5):R151. PubMed ID: 16984661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular outcomes of patients with rheumatoid arthritis prescribed disease modifying anti-rheumatic drugs: a review.
    Giollo A; Bissell LA; Buch MH
    Expert Opin Drug Saf; 2018 Jul; 17(7):697-708. PubMed ID: 29871535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atherosclerosis in rheumatoid arthritis: is it all about inflammation?
    Skeoch S; Bruce IN
    Nat Rev Rheumatol; 2015 Jul; 11(7):390-400. PubMed ID: 25825281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular risk factors in inflammatory arthritis.
    Mirjafari H; Al-Husain A; Bruce IN
    Curr Opin Lipidol; 2011 Aug; 22(4):296-301. PubMed ID: 21670670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.